April 30th 2025
Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.
Subcutaneous Ofatumumab Shows Reduced Injection Reactions in Multiple Sclerosis
June 28th 2024New findings show a similar number of injective-related reactions (IRRs) were reported between the use of ofatumumab (Kesimpta) and ocrelizumab (Ocrevus) in the treatment of multiple sclerosis, but less severe reactions have been associated with ofatumumab.
Read More
Dr Rachel Dalthorp: Addressing Barriers in Postpartum Depression Treatment
June 24th 2024With an effective therapy available for treating postpartum depression, Rachel Dalthorp, MD, believes health care providers need to focus on educating patients and helping them navigate the health system so zuranolone can reach those who need it.
Watch
AxSpA Treatment Intensification in Practice Linked With Higher ASDAS Cutoff Than Recommended
June 22nd 2024In the clinical practice setting, intensifying treatment for axial spondyloarthritis (axSpA) is associated with a higher Ankylosing Spondylitis Disease Activity Score (ASDAS) cutoff value than recommended, new research found.
Read More
Early Detection of PH May Be Key to Improving NSCLC Survival Rates
June 21st 2024This investigation sought to expand knowledge of the impact of comorbid pulmonary hypertension (PH) on diagnosed non–small cell lung cancer (NSCLC), using data from adult patients treated at military hospital facilities within the US.
Read More
Dr Rachel Dalthorp: Zuranolone Improves Access to Postpartum Depression Treatment
June 19th 2024"As a health care provider and as a psychiatrist, it's something that I think about first—instead of step therapy, when I have a patient with postpartum depression, this is what they need to be on," Rachel Dalthorp, MD, explains.
Watch
BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma
June 18th 2024The treatment regimen not only significantly improved progression-free survival (PFS) for patients with advanced stage classic Hodgkin lymphoma but was also better tolerated compared with a 20-year-old regimen being used.
Read More